JEMPERLI has demonstrated clinically meaningful efficacy1

Primary Efficacy Analysis

JEMPERLI demonstrated an overall response rate of 42.3% in patients (n=71) with recurrent or advanced dMMR endometrial cancer who progressed on or after a platinum-based regimen.1

Icon: Objective Response Rate Chart
Icon: Objective Response Rate Chart
Chart: 12.7 percent CR, 29.6 percent PR
  • Overall response rates based on lines of prior therapy2:
    • 42.9% (n=18) in those who received 1 prior line [95% CI (27.7, 59.0)]
    • 41.4% (n=12) in those who received ≥2 prior lines [95% CI (23.5, 61.1)]
    • Due to small sample sizes and wide confidence intervals, results should be interpreted with caution
  • Responses with JEMPERLI were seen across recurrent or advanced endometrial cancer histologies, including serous, squamous, undifferentiated, and mixed carcinoma2

Updated Efficacy Analysis

JEMPERLI demonstrated an overall response rate of 44.7% in patients (n=103) with recurrent or advanced dMMR endometrial cancer who progressed on or after a platinum-based regimen.2

Icon: Objective Response Rate Chart
Chart: Response Rate Chart
Icon: 44.7 percent overall response rate, 95 percent CI (34.9, 54.8)
Chart: 10.7 percent CR, 34.0 percent PR
  • Overall response rates based on lines of prior therapy2:
    • 49.2% (n=32) in those who received 1 prior line (95% CI [36.6, 61.9])
    • 36.8% (n=14) in those who received ≥2 prior lines (95% CI [21.8, 54.0])
    • Due to small sample sizes and wide confidence intervals, results should be interpreted with caution
  • Responses with JEMPERLI were seen across recurrent or advanced endometrial cancer histologies, including serous, squamous, undifferentiated, and mixed carcinoma2

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommend dostarlimab-gxly (JEMPERLI) as a second-line treatment option for recurrent or metastatic dMMR tumors3

Icon: Lightbulb

JEMPERLI has demonstrated a lasting response1,4

In the primary analysis (n=71), median duration of response was not reached1

  • Median follow-up of 14.1 months1*
  • 93.3% of responding patients demonstrated a duration of response ≥6 months1

*Measured from time of first response.

An updated analysis (n=103) showed a median duration of response of 34.7 months2

  • Chart below shows responders in the updated analysis with 103 total patients followed for a median of 20.4 months2†
  • 93.5% of responding patients demonstrated a duration of response ≥6 months2

Median follow-up time is a post hoc analysis of time since initial response.

Graph displaying responders in the updated analysis with 103 total patients followed for a median of 20.4 months

All assessments are based on BICR per RECIST v1.1.

BICR=blinded independent centralized review; RECIST v1.1=Response Evaluation Criteria in Solid Tumors version 1.1.

Icon: JEMPERLI (dostarlimab-gxly) Trial

Explore the pivotal trial
for JEMPERLI.

Icon: JEMPERLI (dostarlimab-gxly) Safety

Learn about the safety and
tolerability profile of JEMPERLI.

Icon: JEMPERLI (dostarlimab-gxly) Dosing and Administration

Find out how to dose and
administer JEMPERLI.